title: The effect of YOCAS©® yoga for musculoskeletal symptoms among breast cancer survivors on hormonal therapy.
abstract: Up to 50% of breast cancer survivors on aromatase inhibitor therapy report musculoskeletal symptoms such as joint and muscle pain, significantly impacting treatment adherence and discontinuation rates. We conducted a secondary data analysis of a nationwide, multi-site, phase II/III randomized, controlled, clinical trial examining the efficacy of yoga for improving musculoskeletal symptoms among breast cancer survivors currently receiving hormone therapy (aromatase inhibitors [AI] or tamoxifen [TAM]). Breast cancer survivors currently receiving AI (N = 95) or TAM (N = 72) with no participation in yoga during the previous 3 months were randomized into 2 arms: (1) standard care monitoring and (2) standard care plus the 4-week yoga intervention (2x/week; 75 min/session) and included in this analysis. The yoga intervention utilized the UR Yoga for Cancer Survivors (YOCAS©(®)) program consisting of breathing exercises, 18 gentle Hatha and restorative yoga postures, and meditation. Musculoskeletal symptoms were assessed pre- and post-intervention. At baseline, AI users reported higher levels of general pain, muscle aches, and total physical discomfort than TAM users (all P ≤ 0.05). Among all breast cancer survivors on hormonal therapy, participants in the yoga group demonstrated greater reductions in musculoskeletal symptoms such as general pain, muscle aches and total physical discomfort from pre- to post-intervention than the control group (all P ≤ 0.05). The severity of musculoskeletal symptoms was higher for AI users compared to TAM users. Among breast cancer survivors on hormone therapy, the brief community-based YOCAS©® intervention significantly reduced general pain, muscle aches, and physical discomfort.
authors: Department of Surgery, University of Rochester, Rochester, NY, USA, Luke_Peppone@urmc.rochester.edu.
authors: Luke J
authors: LJ
authors: Peppone
authors: Michelle C
authors: MC
authors: Janelsins
authors: Charles
authors: C
authors: Kamen
authors: Supriya G
authors: SG
authors: Mohile
authors: Lisa K
authors: LK
authors: Sprod
authors: Jennifer S
authors: JS
authors: Gewandter
authors: Jeffrey J
authors: JJ
authors: Kirshner
authors: Rakesh
authors: R
authors: Gaur
authors: Janet
authors: J
authors: Ruzich
authors: Benjamin T
authors: BT
authors: Esparaz
authors: Karen M
authors: KM
authors: Mustian
mesh_terms: D047072:Aromatase Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000188:drug therapy*; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D017567:Karnofsky Performance Status; D008875:Middle Aged; D009140:Musculoskeletal Diseases / Q000139:chemically induced / Q000628:therapy*; D017741:Survivors; D013629:Tamoxifen / Q000009:adverse effects* / Q000627:therapeutic use; D015013:Yoga
chemical_list: D047072:Aromatase Inhibitors; D013629:Tamoxifen